Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study
Journal of the American Academy of Dermatology · 2026
DOI: 10.1016/j.jaad.2026.02.025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2026. Verfasst von Frank Siebenhaar und 30 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin…. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Pyrazoles, Triazines, Pyrroles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Indolent systemic mastocytosis (ISM), a clonal mast cell disease driven by the KIT D816V mutation, can often cause debilitating dermatologic symptoms. OBJECTIVE: Assess improvement of ISM-related skin manifestations after treatment with avapritinib, a highly selective KIT D816V inhibitor, vs placebo in Part 2 of the PIONEER study (NCT03731260). METHODS: Patients with moderate to severe ISM received avapritinib 25 mg once daily (n = 141) or placebo (n = 71). Endpoints included skin lesion area and pigmentation at week 24, skin mast cell burden, and change in symptoms. RESULTS: Mean percent reduction in lesional surface area was -36.6% with avapritinib vs -1.8% with placebo in the most affected area; 86% vs 0% had improved skin lesion color. Mean percent change in skin mast cell burden decreased with avapritinib (-22.1%) vs placebo (10.1%). Avapritinib vs placebo significantly improved skin symptom domain score (mean change -7.2 vs -2.8; P < .0001), including the individual skin symptoms itching, flushing, and spots. Avapritinib was well tolerated. LIMITATIONS: Photography was optional, so analysis population for lesion area and color were smaller (n = 111) than the overall study population (n = 212). CONCLUSION: Avapritinib treatment improved dermatologic symptoms, decreased skin lesion size, normalized skin lesion color, and reduced skin mast cell burden in patients with ISM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmac…
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
- Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- ARUP Laboratories and Huntsman Cancer Institute, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah.
- Department de dermatologie, Expert Centre of Mastocytosis (CEREMAST) CHU de Toulouse, Toulouse University Hospital - Larrey Hospital, Toulouse, France.
- Institute of Mastocytosis Studies of Castilla-La Mancha, Virgen del Valle Hospital, Toledo, Spain.
Zitieren
APA
Siebenhaar, F., Broesby-Olsen, S., Castells, M., George, T. I., Livideanu, C. B., Álvarez-Twose, I., Panse, J., Barete, S., Reiter, A., Dybedal, I., Akin, C., Van Daele, P., Radia, D. H., Cerquozzi, S., Ustun, C., Sabato, V., Gotlib, J., Rafferty, M., DeAngelo, D. J., …, & Hartmann, K. (2026). Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.02.025
Vancouver
Siebenhaar F, Broesby-Olsen S, Castells M, George TI, Livideanu CB, Álvarez-Twose I, et al. Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.02.025
BibTeX
@article{Siebenhaar2026,
author = {Siebenhaar, Frank and Broesby-Olsen, Sigurd and Castells, Mariana and George, Tracy I and Livideanu, Cristina Bulai and Álvarez-Twose, Iván and Panse, Jens and Barete, Stéphane and Reiter, Andreas and Dybedal, Ingunn and Akin, Cem and Van Daele, Paul and Radia, Deepti H and Cerquozzi, Sonia and Ustun, Celalettin and Sabato, Vito and Gotlib, Jason and Rafferty, Mark and DeAngelo, Daniel J and Schafhausen, Philippe and Ungerstedt, Johanna and Ogbogu, Princess U and Florell, Scott and Wada, David A and Rets, Anton and Lin, Hui-Min and Bidollari, Ilda and Hong, Janet and Shaheen, Daniel and Lampson, Benjamin and Hartmann, Karin},
title = {Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.02.025}
}
EUVIMED